A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

Inclusion Criteria

• •1. Histologically confirmed diagnosis of CD19+ B-ALL per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Lymphoblastic Leukemia (2016.v1)；
• •2. Relapsed or refractory CD19+ B-ALL (meeting one of the following conditions):
• •1. CR not achieved after standardized chemotherapy;
• •2. CR achieved following the first induction, but CR duration is less than 12 months;
• •3. Ineffectively after first or multiple remedial treatments;
• •4. 2 or more relapses;
• •3. The number of primordial cells (lymphoblast and prolymphocyte) in bone marrow is \> 5% (by morphology), and/or \> 1% (by flow cytometry);
• •4. Philadelphia-chromosome-negative (Ph-) patients; or Philadelphia-chromosome-positive (Ph+) patients who cannot tolerate TKI treatments or do not respond to 2 TKI treatments;
• •1. Histologically confirmed diagnosis of DLBCL (NOS), FL, DLBCL transformed from CLL/SLL, PMBCL, and HGBCL per the WHO Classification Criteria for Lymphoma (2016);
• •2. Relapsed or refractory B-NHL (meeting one of the following conditions):
• •1. No response or relapse after second-line or above chemotherapy regimens;
• •2. Primary drug resistance;
• •3. Relapse after auto-HSCT;
• •3. At least one assessable tumor lesion per Lugano 2014 criteria;
• •1. Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol/L;
• •2. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥ 50%;
• •3. No active infection in the lungs, blood oxygen saturation in indoor air is ≥ 92%;
• •4. Estimated survival time ≥ 3 months;
• •5. ECOG performance status 0 to 2;
• •6. Patients or their legal guardians volunteer to participate in the study and sign the informed consent.